NEW YORK--(BUSINESS WIRE)--Enzo Biochem, Inc. (NYSE: ENZ) announced today that the Board of Patents and Interferences has entered judgment in favor of its subsidiary’s patent application for nucleic acid signal amplification over two patents owned by Princeton University. Princeton had conceded priority to Enzo.
